Xencor receives Genentech/Roche termination notice for collaboration; effective Sept 4, 2026

Xencor Inc

Genentech terminated Amended and Restated Collaboration & License Agreement for convenience, effective September 4, 2026.
Sole active product, efbalropendekin alfa, was removed from Roche's pipeline in January 2025.
Xencor ceased cost-sharing in H1 2024; Genentech assumed sole responsibility for development activities.
Termination had been anticipated after Roche's January 2025 pipeline announcement.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Xencor Inc terminated Amended and Restated Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd (effective 2026-09-04).

Action: termination
Agreement: collaboration
Counterparty: Genentech, Inc. and F. Hoffmann-La Roche Ltd
Effective: 2026-09-04

Exact text from the filing

On March 4, 2026, Xencor, Inc. (the “Company”) received a notice of termination of an Amended and Restated Collaboration and License Agreement (the “Agreement”), effective as of June 1, 2024, with Genentech, Inc. (“GNE”) and F. Hoffmann-La Roche Ltd (“Roche” and, GNE and Roche, collectively, “Genentech”), pursuant to which Genentech has elected to terminate the Agreement in its entirety for convenience. The effective date of the termination of the Agreement is September 4, 2026.

View on SEC.gov

317 material agreements filed in the last 30 days. Browse all material agreements →

Xencor Inc filing history →

Source: SEC EDGAR

accession 0001326732-26-000023

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.